News Scinai Immunotherapeutics Ltd.

Stocks

SCNI

US09073Q4029

Biotechnology & Medical Research

Delayed Nasdaq 15:27:34 2026-09-10 EDT			5-day change	1st Jan Change
1.650 ^USD	-3.51%		-15.38%	-76.83%

08-26	Scinai Immunotherapeutics Ltd., H1 2026 Earnings Call, Aug 26, 2026
08-24	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

All News

Mentions Relevance

09-09	Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business	AQ
08-26	Scinai Immunotherapeutics Ltd., H1 2026 Earnings Call, Aug 26, 2026
08-24	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-11	Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration	AQ
08-10	Scinai Biopharma Services Ltd. Wholly Owned Subsidiary of Scinai Immunotherapeutics Ltd. Announces Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration	CI
06-15	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Scinai Immunotherapeutics Ltd. Appoints Eilon Elmalem as Site Head of Yavne Cdmo Facility, Effective June 14, 2026	CI
05-18	Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe	AQ
04-27	Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing	AQ
04-26	Scinai Immunotherapeutics Ltd. announced that it has received $2.5 million in funding	CI
04-23	Scinai Immunotherapeutics Ltd. announced that it expects to receive $2.5 million in funding	CI
04-06	Scinai completes strategic reorganization to establish dedicated CDMO platform and lean R&D structure; outlines 2026 priorities	RE
04-06	Scinai Immunotherapeutics Leverages Strategic Collaboration with Recipharm to Build Integrated Lifecycle CDMO Platform	CI
04-01	Scinai reports full-year 2025 results, with cdmo revenues doubling and strategic expansion through Recipharm collaboration	RE
04-01	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Scinai Immunotherapeutics Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-19	Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026	PR
03-16	Scinai Immunotherapeutics receives Nasdaq notification regarding minimum bid price	RE
03-16	Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price	PR
03-02	Scinai signs second amendment to Pincell option agreement and submits revised EUR12 million non-dilutive Feng application to advance Pc111 through human proof of concept	RE
03-02	Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept	PR
02-25	Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform	CI
02-17	Scinai Immunotherapeutics Ltd. acquired Recipharm Israel Ltd. from Recipharm AB.	CI
01-07	Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL	PR
12-02	Scinai reports nine-month 2025 results as CDMO growth continues and Nanoabs pipeline advances	RE